Cargando…
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Although low-density lipoprotein cholesterol lowering is effective in atherosclerotic cardiovascular disease (ASCVD) prevention, considerable ‘lipid-associated’ residual risk remains, particularly in patients with mild-to-moderate hypertriglyceridaemia (2–10 mmol/L; 176–880 mg/dL). Triglyceride (TG)...
Autores principales: | Parhofer, Klaus G, Chapman, M John, Nordestgaard, Børge G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537801/ https://www.ncbi.nlm.nih.gov/pubmed/33061865 http://dx.doi.org/10.1093/eurheartj/suaa116 |
Ejemplares similares
-
Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
por: Bhatt, Deepak L
Publicado: (2020) -
Beyond cardiovascular medicine: potential future uses of icosapent ethyl
por: Bhatt, Deepak L, et al.
Publicado: (2020) -
Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014) -
Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021) -
Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)